An observational study in COVID and SARS-CoV 2, sponsored by Centre Hospitalier Intercommunal Robert Ballanger. Status unknown at 2 sites in France. Per ClinicalTrials.gov, last updated 2020-04-28.
Sponsored by Centre Hospitalier Intercommunal Robert Ballanger · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 782 studies in COVID-19 with a site in France — 51 open to participants now, 68 under way, 7 of them phase 3. COVID-19 · France.
Among the 782 studies in COVID-19 with a site in France, this one is the 314th largest by planned enrollment of the 486 observational ones that give a count, is one of 499 that started in 2020, is one of 486 observational ones, and was the 107th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →51 of the 782 studies in COVID-19 with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Hospices Civils de Lyon · Sites in France
Ages 8–18
Laboratoire de la Mer · Sites in France
Ages 15 days+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
782 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 57 · Phase 3 64 · Phase 4 4
First in 2016; this study’s year is marked. 499 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 143 is below the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 130 across the 294 interventional studies, 298 across the 486 observational. Of the 530 that completed or were terminated, 39 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 782 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Intercommunal Robert Ballanger is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Centre Hospitalier Intercommunal Robert Ballanger has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
8 of the studies in COVID-19 with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT07882186Assistance Publique - Hôpitaux de ParisAssessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region | 2027-03 |
| NCT03963622Unity Health TorontoCareful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19) | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 782 studies in COVID-19 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive).
This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19, by analyzing associations between treatments and outcomes.
All data are collected in electronical records during routine practice.
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive).
This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19.
Risk factors which will be studied include: baseline characteristics such as medical history and drugs with corresponding administration protocols.
Main outcomes include all-cause mortality, need for mechanical ventilation, for ICU transfer and all relevant biological syndromes.
All data are collected in electronical records during routine practice and additional data may be collected retrospectively.
All patients hospitalized for Covid-19 may be eligible to join this cohort study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Depending on the studied variable (treatment or risk factor)
Depending on the studied variable (treatment or risk factor)
Composite of death and mechanical ventilation
Composite of death and mechanical ventilation
Time frame: At 14-days follow-up
Need for mechanical ventilation
Need for mechanical ventilation
Time frame: At 14-days follow-up
Death
All-cause mortality
Time frame: At 14-days follow-up
Acute kidney injury
As defined by AKIN
Time frame: At 14-days follow-up
Acute respiratory distress syndrome
As defined by Berlin criteria: P/F ratio below 200, with PEEP \> +5 cmH20, radiologic findings compatible with ARDS and not explained by heart failure, occurring within 7 days of an acute pulmonary or non-pulmonary aggression.
Time frame: At 14-days follow-up
Cardiac arrhythmia and conduction disorder
Documented by EKG monitoring
Time frame: At 14-days follow-up
Composite of death and mechanical ventilation
Composite of death and mechanical ventilation
Time frame: Up to 60 days after inclusion
60-days mortality
All cause mortality at 60 days follow-up whenever possible
Time frame: Up to 60 days after inclusion
60-days mechanical ventilation
If patient was mechanically ventilated within 60 days of inclusion
Time frame: Up to 60 days after inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2020 (actual). Primary completion is estimated for Jul 2020, 4 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 4 months is below that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Intercommunal Robert Ballanger